Browsing Tag
Bayer
27 posts
FDA accepts Bayer’s application to expand NUBEQA’s use in prostate cancer treatment
The U.S. Food and Drug Administration (FDA) has accepted Bayer’s supplemental new drug application (sNDA) for NUBEQA (darolutamide),…
Dr. Reddy’s Laboratories, Bayer to distribute Vericiguat for heart failure in India
In a significant move within the Indian healthcare sector, Dr. Reddy’s Laboratories Ltd. and Bayer have announced a…
Bayer announces start of Phase 2 GenePHIT trial for AB-1002
Bayer AG and its subsidiary Asklepios BioPharmaceutical, Inc. (AskBio), have achieved a significant milestone in the fight against…
Bayer and Sun Pharma join forces for new brand of Finerenone in India
In a significant development for the Indian healthcare sector, Sun Pharmaceutical Industries Limited and Bayer have announced a…
Bayer gets Ultravist FDA approval for contrast-enhanced mammography
Bayer has received US Food and Drug Administration (FDA) approval for Ultravist (iopromide) injection, its iodine-based contrast agent,…
Bayer selects OpenText Business Network Cloud Enterprise for B2B integration
OpenText said that German healthcare major Bayer has selected OpenText Business Network Cloud Enterprise as a solution for…
Bayer acquires Scottish imaging AI platform provider Blackford Analysis
Bayer has acquired Blackford Analysis, a Scottish imaging artificial intelligence (AI) platform, to strengthen its footprint in the…
Bayer to sell men’s health product Nebido to Grünenthal in €500m deal
Bayer has agreed to sell Nebido (testosterone undecanoate), its men’s health product, to German pharma company Grünenthal for…
US agri and biotech innovator Andes Ag, Inc. raises $15m in Series A round
Andes Ag, Inc., an agriculture and biotechnology innovator based in California, has raised $15 million in a Series…
Chronos-3 trial results : Aliqopa, rituximab combo meets primary endpoint of PFS, says Bayer
Chronos-3 trial results : Bayer said that the investigational combination of Aliqopa (copanlisib) and rituximab considerably increased progression-free…